Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1885 - Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Clinical Research;  Targeted Therapy

Tumour Site


Santiago Viteri


Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


S. Viteri1, G. Chang2, R. Chiari3, B.C. Cho4, F. Ciardiello5, G. Curigliano6, T. Hida7, D.H. Lee8, W.T..D. Lim9, C. Lin10, A. Martinez11, H. Murakami12, I. Natsume13, M. Nishio14, L. Paz-Ares15, R.A. Soo16, V. Cattan17, E. Gandossi18, H. Heck19, K. Park20

Author affiliations

  • 1 Servicio Oncología Médica, Instituto Universitario USP Dexeus, 8028 - Barcelona/ES
  • 2 Oncology, Taichung Veterans General Hospital, 40705 - Taichung/TW
  • 3 S.c. Oncologia Medica, Azienda Ospedaliera di Perugia S. Maria della Misericordia, 6132 - Perugia/IT
  • 4 Medical Oncology, Yonsei Cancer Center Yonsei University, 6273 - Seoul/KR
  • 5 Dipartimento Medico Di Internistica Clinica E Sperimentale, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 6 Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 7 Department Of Thoracic Oncology, Department of Thoracic Oncology, Aichi/JP
  • 8 Dpt Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 9 Clinical Trial And Epidemiological Sciences, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 10 Department Of Oncology, National Taiwan University Hospital, 100 - Taipei city/TW
  • 11 Servicio Oncología Médica, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 12 Division Of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka/JP
  • 13 Dpt Of Oncology, Yokosuka Kyosai Hospital, Yokosuka Kyosai/JP
  • 14 Thoracic Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo/JP
  • 15 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 16 Haematology-oncology, National University Hospital, 119074 - Singapore/SG
  • 17 Translational Research, Servier France, 92284 - Suresnes/FR
  • 18 Servier Oncology, Servier France, 92284 - Suresnes/FR
  • 19 Dpt Of Pharmacokinetics, Servier, Suresnes/FR
  • 20 Div. Of Heamatology/oncology, Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1885


EGFR T790M mutation is the most common acquired mechanism of resistance in NSCLC patients treated with EGFR-TKI. Alternative mechanisms include activation of the receptor tyrosine kinases MET or AXL. S49076 is a multi-target inhibitor and a potent ATP-competitive TKI that targets MET, AXL and FGFR1/2/3. Here we report phase 1 molecular and safety data of resistant patients without the EGFR T790M mutation that were treated with S49076 combined with gefitinib.


A dose-escalation of S49076 in combination with gefitinib 250 mg once daily was conducted using a modified Bayesian Continual Reassessment Method. Toxicity was evaluated according to Common Terminology Criteria for Adverse Events (AEs), v4.0. Resistant patients were selected according to a tumor molecular profile including presence of the activating EGFR mutation, absence of T790M and with at least one of the following: MET amplification, or MET or AXL overexpression.


The molecular profile screening has been performed in 46 EGFR/T790M-negative tumour samples. In total, 23/46 met the molecular eligibility criteria: 21 with MET dysregulation (11 MET amplification, 20 MET overexpression and 4 both MET / AXL dysregulations), and 2 with AXL overexpression only. Fourteen patients were treated: 4 received the 500 mg dose and 10 received the 600 mg dose, which was considered as the recommended dose. Related AEs included diarrhoea, paronychia, asthenia, nausea, vomiting, ALAT and ASAT increase, anaemia, peripheral oedema and yellow skin, mostly grade 1-2. One patient experienced a DLT at 600 mg (grade 3 stomatitis); 2 patients experienced 3 serious related AEs (asthenia, atrial fibrillation and diarrhoea). No grade 4-5 AEs were reported. Concomitant intake of gefitinib did not appear to modify the S49076 PK profile as compared to previous data. Limited anti-tumour activity was observed in the 12 evaluable patients: 1 partial response and 9 stable diseases.


S49076 combined with gefitinib is well tolerated and data are consistent with the overall safety profile of each drug. The observed frequency of MET dysregulation was comparable to those reported in the literature whereas AXL overexpression was lower than expected.

Clinical trial identification

EudraCT: 2015-00264631.

Legal entity responsible for the study

Servier group.


Servier group.

Editorial Acknowledgement


S. Viteri: BMS: Speaker bureau/ Consultant: Roche G.-C. Chang: Honoraria: Hoffman-La-Roche, Merck Sharp & Dohme, BMS, BI, Pfizer, AstraZeneca, Eli Lilly, Compagny Oncology. G. Curigliano: Speaker: Roche, Pfizer, Novartis. T. Hida: Research funding: Novartis, Pfizer, AstraZeneca. D.H. Lee: Honoraria: AstraZeneca, BMS, Ono Pharm, Merck, Lilly, BI, Pfizer, Novartis, CT Cube, Takeda, Roche, Samyang Biopharma, BMS, Janses, MSD, Mundipharma, CJ Healthcare. H. Murakami: Honoraria, Speaker, Grants and Research: AstraZeneca, BMS, Ono Pharm, Merck, Lilly, Chugai Pharm, BI, Pfizer, Taiho, Novartis. M. Nishio: Speaker fees as Honoraria, Consultant, Research funding: Ono Pharmaceutical, Bristol Myers Squibb, Pfizer, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, Boehringer ingelheim, MSD, Novartis, Daiichi Sankyo Healthcare, Merck Serono, Astellas. L. Paz-Ares: Honoraria: Roche, Lilly, MSD, BMS, Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca, Merck Serono, Amgem, Clovis Oncology. R.A. Soo: Honoraria, Advisory board, Research: AstraZeneca, BMS, Merck, Lilly, Roche, BI, Pfizer, Taiho, Novartis. V. Cattan, E. Gandossi, H. Heck: Employee: Servier. K. Park: Advisor/consultant: Astellas, AstraZeneca, BI, BMS, Clovis, Daiichi Sankyo, EliLilly, GSK, Hanmi, KHK, MSD, Novartis, Roche Research fund; AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.